In the latest trading session, 0.4 million Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares changed hands as the company’s beta touched 1.75. With the company’s most recent per share price at $1.29 changed hands at -$0.06 or -4.44% at last look, the market valuation stands at $99.32M. ONCY’s current price is a discount, trading about -39.53% off its 52-week high of $1.80. The share price had its 52-week low at $0.84, which suggests the last value was 34.88% up since then. When we look at Oncolytics Biotech, Inc.’s average trading volume, we note the 10-day average is 1.26 million shares, with the 3-month average coming to 381.99K.
Analysts gave the Oncolytics Biotech, Inc. (ONCY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ONCY as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Oncolytics Biotech, Inc.’s EPS for the current quarter is expected to be -0.07.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Oncolytics Biotech, Inc. (NASDAQ:ONCY) trade information
Instantly ONCY was in red as seen in intraday trades today. With action 12.17%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -4.44%, with the 5-day performance at 12.17% in the green. However, in the 30-day time frame, Oncolytics Biotech, Inc. (NASDAQ:ONCY) is 39.63% up. Looking at the short shares, we see there were 1.02 million shares sold at short interest cover period of 5.43 days.
Oncolytics Biotech, Inc. (ONCY) estimates and forecasts
Data shows that the Oncolytics Biotech, Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 24.04% over the past 6 months, a 3.33% in annual growth rate that is considerably lower than the industry average of 17.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.01%. The 2024 estimates are for Oncolytics Biotech, Inc. earnings to increase by 6.08%.
ONCY Dividends
Oncolytics Biotech, Inc. is expected to release its next quarterly earnings report on 2024-Nov-01.
Oncolytics Biotech, Inc. (NASDAQ:ONCY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.82% of Oncolytics Biotech, Inc. shares while 1.72% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 1.79%. There are 1.72% institutions holding the Oncolytics Biotech, Inc. stock share, with INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 0.2637% of the shares, roughly 0.2 million ONCY shares worth $0.2 million.
SEEDS INVESTOR LLC holds the second largest percentage of outstanding shares, with 0.2524% or 0.19 million shares worth $0.19 million as of 2024-06-30.
With 41.94 shares estimated at $52846.0 under it, the former controlled 0.05% of total outstanding shares.
